Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Skin Cancer, Skin Cancer Melanoma, Skin Cancers - Basal Cell Carcinoma, Skin Cancer, Squamous Cell
Conditions
Keywords
multiple sclerosis and skin cancer, fingolimod, disease modifying therapy, FTY720, fingolimod and skin cancer
Brief summary
The goal of this retrospective observational study is to investigate the long-term safety of Fingolimod in individuals with Multiple Sclerosis (MS), specifically focusing on the risk of developing skin cancer. The main question it aims to answer is: • Does the use of Fingolimod increase the incidence of skin cancer in individuals with MS compared to those using other disease-modifying therapies? Participants who are new users of Fingolimod or other active comparators as part of their regular medical care for MS will be included in this study. Researchers will use advanced causal inference techniques to analyze healthcare data and compare the incidence of skin cancer between these groups.
Interventions
DRUGFingolimod
patients who received fingolimod for treating RRMS
DRUGNatalizumab
patients who received natalizumab for treating RRMS (active comparator)
patients who received dimethyl fumarate for treating RRMS (active comparator)
DRUGAlemtuzumab
patients who received alemtuzumab for treating RRMS (active comparator)
DRUGTeriflunomide
patients who received teriflunomide for treating RRMS (active comparator)
Sponsors
University of British Columbia
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Identified MS cohort with hospital/physician and prescription claims classified according to the international classification of disease codes and drug identification numbers respectively, using a validated case definition. This case definition requires an individual to have at least three health care encounters (any combination of inpatient encounter, outpatient encounter, or DMT dispensation) for MS in a 1-year window * MS patients who initiated and used fingolimod, natalizumab, alemtuzumab, dimethyl fumarate, or teriflunomide as monotherapy following MS identification.
Exclusion criteria
* Pediatric (\<18 years old) MS cases. * MS cases with less than three years of baseline data before the first drug dispensation. * MS cases with skin cancer in the three-year baseline period
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants who developed skin cancer | From Index drug dispensation to the first of the following events, whichever occurred first: development of skin cancer; lost to follow-up; death; administrative end of follow-up; initiation of a comparator drug, assessed up to 180 months. | In this outcome measure, participants who developed skin cancer after receiving the respective DMT treatments are reported. ICD 9/10 codes were used for the diagnosis of skin cancer (melanoma and non-melanoma skin cancers). Skin cancers were treated as a composite outcome of basal cell carcinoma, squamous cell carcinoma, and melanoma, as well as disaggregated by skin cancer subtypes. |
| Time to development of skin cancer | From Index drug dispensation to the first of the following events, whichever occurred first: development of skin cancer; lost to follow-up; death; administrative end of follow-up; initiation of a comparator drug, assessed up to 180 months. | Time to development of skin cancer is defined as the time from the index date (drug initiation) to the development of skin cancer. ICD 9/10 codes were used for the diagnosis of skin cancer (melanoma and non-melanoma skin cancers). Skin cancers were treated as a composite outcome of basal cell carcinoma, squamous cell carcinoma, and melanoma, as well as disaggregated by skin cancer subtypes. |
Outcome results
None listed